IP Library Granted Patent US 8,454,973
Granted Patent B2
US 8,454,973 · App. 11/660,794 · Granted Jun 4, 2013

Modified human hepatitis C virus genomic RNA that can be autonomously replicated

Inventors: Takaji Wakita (Tokyo, JP); Takanobu Kato (Aichi, JP); Tomoko Date (Kanagawa, JP); Michiko Miyamoto (Tokyo, JP); Ralf Bartenschlager (Schriesheim, DE); Jun-ichi Tanabe (Kanagawa, JP); Saburo Sone (Kanagawa, JP)
Assignees: Tokyo Metropolitan Institute of Medical Science; Toray Industries, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,454,973
App. No.
11/660,794
Granted
Jun 4, 2013
Kind
B2
Abstract

The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5′ untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3′ untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.

Claims (13)

1. A modified hepatitis C virus genomic RNA comprising genomic RNA portions of two or more strains of hepatitis C viruses, which comprises a 5′ untranslated region, a core protein coding sequence, an E1 protein coding sequence, an E2 protein coding sequence, a p7 protein coding sequence, an NS2 protein coding sequence, a partial RNA sequence encoding NS3, NS4A, NS4B, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO:1, and a 3′ untranslated region, wherein said modified hepatitis C virus genomic RNA is autonomously replicated and is capable of producing infectious hepatitis C virus particles in a cultured cell system, wherein the core protein coding sequence, the E1 protein coding sequence, the E2 protein coding sequence, and the p7 protein coding sequence are from the hepatitis C virus strain of genotype 1b, wherein the NS2 protein coding sequence is from the hepatitis C virus strain selected from the group consisting of genotype 1b and genotype 2a, and wherein the 5′ untranslated region and the 3′ untranslated region are from the JFH-1 strain,

wherein the hepatitis C virus strain of genotype 1b is an HCV-TH strain, and

wherein:

(i) the core protein coding sequence, the E1 protein coding sequence, the E2 protein coding sequence, and the p7 protein coding sequence are from the HCV-TH strain of genotype 1b, and the NS2 protein coding sequence is from the JFH-1 strain of genotype 2a.

2. A hepatic cell-derived virus vector, which comprises the modified hepatitis C virus genomic RNA according to claim 1 .

3. An isolated cell comprising the modified hepatitis C virus genomic RNA according to claim 1 wherein the hepatitis C virus genomic RNA is replicated and wherein the cell generates virus particles.

4. Isolated Hepatitis C virus particles, which are obtained from a culture obtained by culturing the cell according to claim 3 .

5. An immunogenic hepatitis C virus composition comprising hepatitis C virus particles according to claim 4 .

6. An isolated hepatitis C virus-infected cell, which is infected with the hepatitis C virus particles according to claim 4 .

7. A method for producing hepatitis C virus particles, wherein the method comprises culturing the cell according to claim 3 and recovering virus particles from the culture.

8. A method for producing a hepatitis C virus-infected cell, comprising culturing the cell according to claim 3 and infecting another cell with the virus particles contained in the culture.

9. The isolated cell according to claim 3 , wherein the cell is selected from the group consisting of a Huh-7 cell, a HepG2 cell, an IMY-N9 cell, a HeLa cell, and a 293 cell.

10. The modified hepatitis C virus genomic RNA according to claim 1 , wherein the hepatitis C virus genomic RNA comprises SEQ ID NO: 11.

Assignments (2)
CHANGE OF NAME Recorded Sep 20, 2011
From: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH
To: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Reel/Frame 026931/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2007
From: WAKITA, TAKAJI; KATO, TAKANOBU; DATE, TOMOKO; MIYAMOTO, MICHIKO; BARTENSCHLAGER, RALF; TANABE, JUN-ICHI; SONE, SABURO
To: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH; TORAY INDUSTRIES, INC.
Reel/Frame 018980/0115 →
Priority Claims (4)
JP 2004-243975 · Aug 24, 2004 · national
JP 2004-290801 · Oct 1, 2004 · national
JP 2005-069527 · Mar 11, 2005 · national
JP 2005-069725 · Mar 11, 2005 · national
Continuity (1)
Related Publication 20090176200A1 · Jul 9, 2009